Comparative Pharmacology
Head-to-head clinical analysis: TERAZOSIN HYDROCHLORIDE versus UROXATRAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TERAZOSIN HYDROCHLORIDE versus UROXATRAL.
TERAZOSIN HYDROCHLORIDE vs UROXATRAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective alpha-1 adrenergic receptor antagonist; inhibits vasoconstriction and relaxes smooth muscle in blood vessels and prostate.
Selective antagonist of postsynaptic alpha1A-adrenoceptors in the prostate, bladder base, and prostatic urethra, leading to relaxation of smooth muscle and improved urinary flow.
Adults: Initial: 1 mg orally once daily at bedtime. May increase gradually to 2–5 mg once daily. Maximum: 20 mg/day.
10 mg orally once daily, immediately after the same meal each day.
None Documented
None Documented
Terminal elimination half-life is 9–12 hours in patients with normal renal function; may be prolonged in renal impairment.
The terminal elimination half-life is approximately 5 to 9 hours in healthy young subjects, and 6 to 10 hours in elderly patients. This supports once-daily dosing, with steady state achieved after 3-5 days.
Approximately 40% of the dose is excreted in urine (20% as unchanged drug) and 60% in feces via biliary elimination.
After oral administration, approximately 11% of the dose is excreted unchanged in urine, while 49% is excreted as metabolites in urine and 22% in feces. Overall, renal elimination accounts for about 60% of total clearance.
Category A/B
Category C
Alpha-1 Blocker
Alpha-1 Blocker